Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

36.30
-0.5400-1.47%
Post-market: 36.360.0600+0.17%19:51 EDT
Volume:6.19M
Turnover:225.49M
Market Cap:26.22B
PE:-77.23
High:37.18
Open:37.03
Low:36.23
Close:36.84
52wk High:37.97
52wk Low:11.60
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.12
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.20
PE(LYR):-67.22

Loading ...

Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success

Simply Wall St.
·
Mar 29

BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis

Reuters
·
Mar 29

Roivant’s brepocitinib beats placebo in Phase 3 dermatomyositis trial, NEJM reports

Reuters
·
Mar 29

Roivant Sciences Ltd - FDA Grants Priority Review to Brepocitinib Nda With Pdufa Date in Q3 2026

THOMSON REUTERS
·
Mar 29

New England Journal of Medicine Publishes Positive Phase 3 Valor Trial Results of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Mar 29

Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?

Simply Wall St.
·
Mar 28

Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit

Reuters
·
Mar 23

Bernstein bullish on Roivant Sciences, initiates with an Outperform

TIPRANKS
·
Mar 20

Roivant Sciences Ltd : Bernstein Initiates Coverage With Outperform Rating; Target Price $35

THOMSON REUTERS
·
Mar 20

Roivant Sciences President and Immunovant CEO Eric Venker disposes of USD 5.65 million in common shares

Reuters
·
Mar 20

Roivant Sciences director Melissa B. Epperly disposes of USD 1.2 million in common shares

Reuters
·
Mar 19

Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Mar 09

Moderna litigation outcome ‘favorable,’ but leaves some risk, says BofA

TIPRANKS
·
Mar 04

Moderna to Pay $2.25 Billion Settlement to Resolve LNP Patent Dispute

Deep News
·
Mar 04

Guggenheim Sticks to Their Buy Rating for Roivant Sciences (ROIV)

TIPRANKS
·
Mar 04

Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 04

BUZZ-Street View: Wall Street views Moderna's legal settlement as clearing a major overhang

Reuters
·
Mar 04

Roivant Sciences price target raised to $34 from $33 at H.C. Wainwright

TIPRANKS
·
Mar 04

Moderna Agrees to Pay up to $2.25 Billion to Settle COVID Vaccine Patent Dispute

Reuters
·
Mar 04

Roivant Sciences Raises Buyback Program to $1 Billion

Dow Jones
·
Mar 04